Negative modulation of GABA A α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats

Psychopharmacology

Volumn 221, Issue 3, 2012, Pages 451-468

  Redrobe, John P ^a   Elster, Lisbeth ^a   Frederiksen, Kristen ^a   Bundgaard, Christoffer ^a   De Jong, Inge E M ^a   Smith, Garrick P ^a   Bruun, Anne Techau ^a   Larsen, Peter H ^a   Didriksen, Michael ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Attentional set shifting; Cognition; Early postnatal PCP; GABA alpha5 receptors; Negative allosteric modulator; Novel object recognition; Rat; Sub chronic PCP

Indexed keywords

3 BROMO 10 DIFLUOROMETHYL 9H IMIDAZO[1,5 A][1,2,4]TRIAZOLO[1,5 D][1,4]BENZODIAZEPINE; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 7 ACETYLENO 1,3 DIHYDRO 1 METHYL 5 PHENYL 2H 1,4 BENZODIAZEPIN 2 ONE; AMPHETAMINE; GABAERGIC RECEPTOR AFFECTING AGENT; PARVALBUMIN; PHENCYCLIDINE; RO 4938581; UNCLASSIFIED DRUG; 3 BROMO 10 DIFLUOROMETHYL 9H IMIDAZO(1,5 A)(1,2,4)TRIAZOLO(1,5 D)(1,4)BENZODIAZEPINE; 3-BROMO-10-DIFLUOROMETHYL-9H-IMIDAZO(1,5-A)(1,2,4)TRIAZOLO(1,5-D)(1,4)BENZODIAZEPINE; 4 AMINOBUTYRIC ACID A RECEPTOR; BENZODIAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; GABRA5 PROTEIN, RAT; IMIDAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; EX VIVO STUDY; HYPERACTIVITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NEUROMODULATION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECOGNITION; TASK PERFORMANCE; ANIMAL; CHEMICALLY INDUCED DISORDER; CHO CELL; CRICETULUS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; FEMALE; HAMSTER; HYPERKINESIA; METABOLISM; OOCYTE; PATHOPHYSIOLOGY; SCHIZOPHRENIA; VALIDATION STUDY; WISTAR RAT; XENOPUS LAEVIS;

AMPHETAMINE; ANIMALS; BENZODIAZEPINES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHO CELLS; COGNITION DISORDERS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYPERKINESIS; IMIDAZOLES; MALE; OOCYTES; PARVALBUMINS; PHENCYCLIDINE; PREFRONTAL CORTEX; RATS; RATS, WISTAR; RECEPTORS, GABA-A; SCHIZOPHRENIA; XENOPUS LAEVIS;

EID: 84862659903     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2593-9     Document Type: Article

References (101)

1. Aleman A, Hijman R, de Haan EH, Kahn RS (1999)Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 156:1358-1366 (Pubitemid 29416531)
2. Arnt J (1995) Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. Eur J Pharmacol 283:55-62
3. Atack JR (2010) Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA. Pharmacol Ther 125:11-26
4. Atack JR (2011) GABAA receptor subtype-selective modulators. II. α5-Selective inverse agonists for cognition enhancement. Curr Top Med Chem 11:1203-1214
5. Atack JR, Bayley PJ, Seabrook GR, Wafford KA, McKernan RM, Dawson GR (2006) L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors. Neuropharmacology 51:1023-1029 (Pubitemid 44691810)
6. Ballard TM, Knoflach F, Prinssen E, Borroni E, Vivian JA, Basile J, Gasser R, Moreau JL, Wettstein JG, Buettelmann B, Knust H, Thomas AW, Trube G, Hernandez MC (2009) RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors. Psychopharmacology 202:207-223
7. Barch DM, Braver TS, Carter CS, Poldrack RA, Robbins TW (2009) CNTRICS final task selection: executive control. Schizophr Bull 35:115-135
8. Bartos M, Vida I, Jonas P (2007) Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat Rev Neurosci 8:45-56 (Pubitemid 46011998)
9. Bayer SA, Altman J, Russo RJ, Zhang X (1993) Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 14:83-144 (Pubitemid 23195769)
10. Beasley CL, Reynolds GP (1997) Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 24:349-355 (Pubitemid 27163247)
11. Belelli D, Harrison NL, Maguire J, Macdonald RL, Walker MC, Cope DW (2009) Extrasynaptic GABAA receptors: form, pharmacology, and function. J Neurosci 29:12757-12763
12. Berg EA (1948) A simple objective technique for measuring flexibility in thinking. J Gen Psychol 39:15-22
13. Birrell JM, Brown VJ (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20:4320-4324 (Pubitemid 30365702)
14. Broberg BV, Dias R, Glenthøj BY, Olsen CK (2008) Evaluation of a neurodevelopmental model of schizophrenia-early postnatal PCP treatment in attentional set-shifting. Behav Brain Res 190:160-163
15. Broberg BV, Glenthøj BY, Dias R, Larsen DB, Olsen CK (2009) Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia: sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology 206:631-640
16. Brown MW, Warburton EC, Aggleton JP (2010) Recognition memory: material, processes, and substrates. Hippocampus 20:1228-1244
17. Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR (2011) A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry 69:442-449
18. Cho RY, Konecky RO, Carter CS (2006) Impairments in frontal cortical gamma synchrony and cognitive control in schizophrenia. Proc Natl Acad Sci USA 103:19878-19883 (Pubitemid 46037524)
19. Clancy B, Darlington RB, Finlay BL (2001) Translating developmental time across mammalian species. Neuroscience 105:7-17 (Pubitemid 32722089)
20. Clare L, McKenna PJ, Mortimer AM, Baddeley AD (1993) Memory in schizophrenia: what is impaired and what is preserved? Neuropsychologia 31:1225-1241 (Pubitemid 23345000)
21. Clark RE, Zola SM, Squire LR (2000) Impaired recognition memory in rats after damage to the hippocampus. J Neurosci 20:8853-8860
22. Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ (2003) Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28:265-275
23. Collinson N, Kuenzi FM, Jarolimek W, Maubach KA, Cothliff R, Sur C, Smith A, Otu FM, Howell O, Atack JR, McKernan RM, Seabrook GR, Dawson GR, Whiting PJ, Rosahl TW (2002) Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci 22:5572-5580
24. Cooke SF, Bliss TV (2005) Long-term potentiation and cognitive drug discovery. Curr Opin Investig Drugs 6:25-34
25. Damgaard T, Larsen DB, Hansen SL, Grayson B, Neill JC, Plath N (2010) Positive modulation of alpha-amino-3-hydroxy-5-methyl- 4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. Behav Brain Res 207:144-150
26. Dawson GR, Maubach KA, Collinson N, Cobain M, Everitt BJ, MacLeod AM, Choudhury HI, McDonald LM, Pillai G, Rycroft W, Smith AJ, Sternfeld F, Tattersall FD, Wafford KA, Reynolds DS, Seabrook GR, Atack JR (2006) An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition. J Pharmacol Exp Ther 316:1335-1345 (Pubitemid 43345310)
27. Dere E, Huston JP, De Souza Silva MA (2007) The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 31:673-704 (Pubitemid 46670336)
28. Deutsch SI, Mastropaolo J, Rosse RB (1998) Neurodevelopmental consequences of early exposure to phencyclidine and related drugs. Clin Neuropharmacol 21:320-332 (Pubitemid 28543946)
29. Egerton A, Reid L, McKerchar CE, Morris BJ, Pratt JA (2005) Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology 179:77-84 (Pubitemid 40576694)
30. Elliott R, McKenna PJ, Robbins TW, Sahakian BJ (1995) Neuropsychological evidence for frontostriatal dysfunction in schizophrenia. Psychol Med 25:619-630
31. Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: Behavioural data. Behav Brain Res 31:47-59
32. Ferrarelli F, Massimini M, Peterson MJ, Riedner BA, Lazar M, Murphy MJ, Huber R, Rosanova M, Alexander AL, Kalin N, Tononi G (2008) Reduced evoked gamma oscillations in the frontal cortex in schizophrenia patients: a TMS/EEG study. Am J Psychiatry 165:996-1005
33. Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L (2011) The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev 35:573-588
34. Gerdjikov TV, Rudolph U, Keist R, Mohler H, Feldon J, Yee BK (2008) Hippocampal alpha 5 subunit-containing GABA A receptors are involved in the development of the latent inhibition effect. Neurobiol Learn Mem 89:87-94 (Pubitemid 350235962)
35. Gill KM, Lodge DJ, Cook JM, Aras S, Grace AA (2011) A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. Neuropsychopharmacology 36:1903-1911. doi:10.1038/npp.2011.76
36. Gilmour G, Dix S, Fellini L, Gastambide F, Plath N, Steckler T, Talpos J, Tricklebank M (2011) NMDA receptors, cognition and schizophrenia-testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology. doi:10.1016/j.neuropharm.2011.03.015
37. Glykys J, Mann EO, Mody I (2008) Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus? J Neurosci 28:1421-1426 (Pubitemid 351231514)
38. Goetghebeur P, Dias R (2009) Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat: a back translational study. Pyschopharmacology 202:287-293
39. Goetghebeur PJ, Lerdrup L, Sylvest A, Dias R (2010) Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model. Psychopharmacology 212:635-642
40. Grace AA (2011) Dopamine system dysregulation by the hippocampus: implications for the pathophysiology and treatment of schizophrenia. Neuropharmacology. doi:10.1016/j.neuropharm.2011.05.011
41. Green MF, Bracha HS, Satz P, Christenson CD (1994) Preliminary evidence for an association between minor physical anomalies and second trimester neurodevelopment in schizophrenia. Psychiatry Res 53:119-127 (Pubitemid 24289069)
42. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR (2004) Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry 56:301-307 (Pubitemid 39164514)
43. Hadingham KL, Wingrove PB, Wafford KA, Bain C, Kemp JA, Palmer KJ, Wilson AW, Wilcox AS, Sikela JM, Ragan CI, Whiting PJ (1993) Role of the beta subunit in determining the pharmacology of human gamma-aminobutyric acid type A receptors. Mol Pharmacol 44:1211-1218 (Pubitemid 24008605)
44. Harvey PD, Keefe RSE (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158:176-184 (Pubitemid 32116511)
45. Hasan A, Nitsche MA, Rein B, Schneider-Axmann T, Guse B, Gruber O, Falkai P, Wobrock T (2011) Dysfunctional long-term potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. Behav Brain Res 224:15-22
46. Hauser J, Rudolph U, Keist R, Mohler H, Feldon J, Yee BK (2005) Hippocampal alpha5 subunit-containing GABAA receptors modulate the expression of prepulse inhibition. Mol Psychiatry 10:201-207 (Pubitemid 40188514)
47. Haut MW, Cahill J, Cutlip WD, Stevenson JM, Makela EH, Bloomfield SM(1996) On the nature ofWisconsin card sorting test performance in schizophrenia. Psychiatry Res 65:15-22 (Pubitemid 26387209)
48. Heckers S, Curran T, Goff D, Rauch SL, Fischman AJ, Alpert NM, Schacter DL (2000) Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia. Biol Psychiatry 48:651-657
49. Hetem LA, Danion JM, Diemunsch P, Brandt C (2000) Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology 152:283-288
50. Honey GD, O'Loughlin C, Turner DC, Pomarol-Clotet E, Corlett PR, Fletcher PC (2006) The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia. Neuropsychopharmacology 31:413-423 (Pubitemid 43113405)
51. Huang Q, Zhang W, Liu R, McKernan RM, Cook JM (1996) Benzofused benzodiazepines employed as topological probes for the study of benzodiazepine receptor subtypes. Med Chem Res 6:384-391 (Pubitemid 126441515)
52. Huang Q, He X, Ma C, Liu R, Yu S, Dayer CA, Wenger GR, McKernan R, Cook JM (2000) Pharmacophore/receptor models for GABAA/BzR subtypes (α1β3γ2, α5β3γ2, and α6β3γ2) via a comprehensive ligand-mapping approach. J Med Chem 43:71-95 (Pubitemid 30055764)
53. Hutton SB, Puri BK, Duncan LJ, Robbins TW, Barnes TRE, Joyce EM (1998) Executive function in first-episode schizophrenia. Psychol Med 28:463-473 (Pubitemid 28197561)
54. Idris N, Neill J, Grayson B, Bang-Andersen B, Witten LM, Brennum LT, Arnt J (2010) Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT(2A) receptor mechanisms. Psychopharmacology 208:23-36
55. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K et al (1999) Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283:70-74 (Pubitemid 29044848)
56. Jenkins TA, Elliott JJ, Ardis TC, Cahir M, Reynolds GP, Bell R, Cooper SJ (2010) Effect of subchronic phencyclidine administration on sucrose preference and hippocampal parvalbumin immunoreactivity in the rat. Behav Brain Res 208:479-483
57. Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225 (Pubitemid 29067401)
58. Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327-338 (Pubitemid 36124162)
59. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA, CATIE Investigators, Neurocognitive Working Group (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64:633-647 (Pubitemid 46878665)
60. Knust H, Achermann G, Ballard T, Buettelmann B, Gasser R, Fischer H, Hernandez MC, Knoflach F, Koblet A, Stadler H, Thomas AW, Trube G, Waldmeier P (2009) The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment of cognitive dysfunction. Bioorg Med Chem Lett 19:5940-5944
61. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19
62. Leeson VC, Robbins TW, Matheson E, Hutton SB, Ron MA, Barnes TR, Joyce EM (2009) Discrimination learning, reversal, and setshifting in first-episode schizophrenia: stability over 6 years and specific associations with medication type and disorganization syndrome. Biol Psychiatry 66:586-593
63. Lewis DA, Cho RY, Carter CS, Eklund K, Forster S, Kelly MA, Montrose D (2008) Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry 165:1585-1593
64. Manns JR, Stark CEL, Squire LR (2000) The visual paired-comparison task as a measure of declarative memory. Proc Natl Acad Sci USA 97:12375-12379
65. Martin LJ, Oh GH, Orser BA (2009) Etomidate targets alpha5 gamma-aminobutyric acid subtype A receptors to regulate synaptic plasticity and memory blockade. Anesthesiology 111:1025-1035
66. McKernan RM, Whiting PJ (1996) Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci 19:139-143
67. McKernan RM, Wafford K, Quirk K, Hadingham KL, Harley EA, Ragan CI, Whiting PJ (1995) The pharmacology of the benzodiazepine site of the GABA-A receptor is dependent on the type of gamma-subunit present. J Recept Signal Transduct Res 15:173-183
68. McLean SL, Beck JP, Woolley ML, Neill JC (2008) A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav Brain Res 189:152-158
69. McLean SL, Grayson B, Idris NF, Lesage AS, Pemberton DJ, Mackie C, Neill JC (2010) Activation of alpha7 nicotinic receptors improves phencyclidine- induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia. Eur Neuropsychopharmacol 21:333-343
70. Möhler H (2009) Role of GABAA receptors in cognition. Biochem Soc Trans 37:1328-1333
71. Murray GK, Cheng F, Clark L, Barnett JH, Blackwell AD, Fletcher PC, Robbins TW, Bullmore ET, Jones PB (2008) Reinforcement and reversal learning in first-episode psychosis. Schizophr Bull 34:848-855
72. Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128:419-432
73. Nutt D (2006) GABAA receptors: subtypes, regional distribution, and function. J Clin Sleep Med 2:S7-S11
74. Nutt DJ, Besson M, Wilson SJ, Dawson GR, Lingford-Hughes AR (2007) Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology 53:810-8220
75. O'Tuathaigh CM, Waddington JL (2010) Mutant mouse models: phenotypic relationships to domains of psychopathology and pathobiology in schizophrenia. Schizophr Bull 36:243-245
76. Pantelis C, Barber FZ, Barnes TR, Nelson HE, Owen AM, Robbins TW (1999) Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37:251-270 (Pubitemid 29298095)
77. Pedersen CS, Goetghebeur P, Dias R (2009) Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID/ED) performance. J Neurosci Methods 185:66-69
78. Pratt JA, Winchester C, Egerton A, Cochran SM, Morris BJ (2008) Modelling prefrontal cortex deficits in schizophrenia: implications for treatment. Br J Pharmacol 153(Suppl 1):S465-S470 (Pubitemid 351341020)
79. Rezvani AH (2006) Involvement of the NMDA system in learning and memory. In: Levin ED, Buccafusco JJ (eds) Animal models of cognitive impairment, Chapter 4. CRC, Boca Raton 37-48
80. Rodefer JS, Murphy ER, Baxter MG (2005) PDE10A inhibition reverses PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21:1070-1076 (Pubitemid 40461058)
81. Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J (2008) Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 33:2657-2666
82. Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, Robbins TW (1988) A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain 111:695-718
83. Sharma T, Antonova L (2003) Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psychiatr Clin North Am 26:25-40 (Pubitemid 36384346)
84. Sieghart W, Sperk G (2002) Subunit composition, distribution and function of GABA(A) receptor subtypes. Curr Top Med Chem 2:795-816
85. 3H]RY 80: a high-affinity, selective ligand for gamma-aminobutyric acidA receptors containing alpha-5 subunits. J Pharmacol Exp Ther 283:488-493
86. Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, Meltzer HY (2010) Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimivanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 332:622-631
87. Sotty F, Damgaard T, Montezinho LP, Mørk A, Olsen CK, Bundgaard C, Husum H (2009a) Antipsychotic-like effect of retigabine [N-(2-Amino-4- (fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission. J Pharmacol Exp Ther 328:951-962
88. Sotty F, Montezinho LP, Steiniger-Brach B, Nielsen J (2009b) Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons. J Neurochem 109:766-775
89. Tek C, Gold J, Blaxton T, Wilk C, McMahon RP, Buchanan RW (2002) Visual perceptual and working memory impairments in schizophrenia. Arch Gen Psychiatry 59:146-153 (Pubitemid 34137384)
90. Thierry AM, Gioanni Y, Dégénétais E, Glowinski J (2000) Hippocampo-prefrontal cortex pathway: anatomical and electrophysiological characteristics. Hippocampus 10:411-419
91. Towers SK, Gloveli T, Traub RD, Driver JE, Engel D, Fradley R, Rosahl TW, Maubach K, Buhl EH, Whittington MA (2004) Alpha 5 subunit-containing GABAA receptors affect the dynamic range of mouse hippocampal kainate-induced gamma frequency oscillations in vitro. J Physiol 559:721-728 (Pubitemid 39276163)
92. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ (2004) Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29:1363-1373 (Pubitemid 38780659)
93. Uhlhaas PJ, Haenschel C, Nikolić D, Singer W (2008) The role of oscillations and synchrony in cortical networks and their putative relevance for the pathophysiology of schizophrenia. Schizophr Bull 34:927-943
94. Wang XJ (2010) Neurophysiological and computational principles of cortical rhythms in cognition. Physiol Rev 90:1195-1268
95. Wang CZ, Johnson KM (2005) Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat. J Neurosci Res 81:284-292 (Pubitemid 41153343)
96. Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM (2001) Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107:535-550 (Pubitemid 33097492)
97. Waters KA, Burnham KE, O'Connor D, Dawson GR, Dias R (2005) Assessment of modafinil on attentional processes in a five-choice serial reaction time test in the rat. J Psychopharmacol 19:149-158 (Pubitemid 40577219)
98. Wilson C, Terry AV Jr (2010) Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development. Clin Schizophr Relat Psychoses 4:124-137
99. Winters BD, Saksida LM, Bussey TJ (2008) Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci Biobehav Rev 32:1055-1070
100. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122:150-202
101. Zhang ZJ, Reynolds GP (2002) A selective decrease in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia. Schizophr Res 55:1-10 (Pubitemid 34310531)